Oliver J Kennedy1, Nicola Pirastu2, Robin Poole3, Jonathan A Fallowfield4, Peter C Hayes4, Eryk J Grzeszkowiak2, Maarten W Taal5, James F Wilson6, Julie Parkes3, Paul J Roderick3. 1. Primary Care & Population Sciences Faculty of Medicine, University of Southampton, Southampton, United Kingdom. Electronic address: ok4g13@soton.ac.uk. 2. Centre for Global Health Research, Usher Institute for Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, United Kingdom. 3. Primary Care & Population Sciences Faculty of Medicine, University of Southampton, Southampton, United Kingdom. 4. University of Edinburgh Centre for Inflammation Research, Queen's Medical Research Institute, Edinburgh BioQuarter, Edinburgh, United Kingdom. 5. Division of Medical Sciences and Graduate Entry Medicine, University of Nottingham, Nottingham, United Kingdom. 6. Centre for Global Health Research, Usher Institute for Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, United Kingdom; MRC Human Genetic Unit, Institute of Genetic and Molecular Medicine, University of Edinburgh, Western General Hospital, Edinburgh, United Kingdom.
Abstract
RATIONALE & OBJECTIVE: Chronic kidney disease (CKD) is a leading cause of morbidity and mortality worldwide, with limited strategies for prevention and treatment. Coffee is a complex mixture of chemicals, and consumption has been associated with mostly beneficial health outcomes. This work aimed to determine the impact of coffee consumption on kidney function. STUDY DESIGN: Genome-wide association study (GWAS) and Mendelian randomization. SETTING & PARTICIPANTS: UK Biobank baseline data were used for a coffee consumption GWAS and included 227,666 participants. CKDGen Consortium data were used for kidney outcomes and included 133,814 participants (12,385 cases of CKD) of mostly European ancestry across various countries. EXPOSURE: Coffee consumption. OUTCOMES: Estimated glomerular filtration rate (eGFR), CKD GFR categories 3 to 5 (G3-G5; eGFR<60mL/min/1.73m2), and albuminuria. ANALYTICAL APPROACH: GWAS to identify single-nucleotide polymorphisms (SNPs) associated with coffee consumption in UK Biobank and use of those SNPs in Mendelian randomization analyses of coffee consumption and kidney outcomes in CKDGen. RESULTS: 2,126 SNPs were associated with coffee consumption (P<5×10-8), 25 of which were independent and available in CKDGen. Drinking an extra cup of coffee per day conferred a protective effect against CKD G3-G5 (OR, 0.84; 95% CI, 0.72-0.98; P=0.03) and albuminuria (OR, 0.81; 95% CI, 0.67-0.97; P=0.02). An extra cup was also associated with higher eGFR (β=0.022; P=1.6×10-6) after removal of 3 SNPs responsible for significant heterogeneity (Cochran Q P = 3.5×10-15). LIMITATIONS: Assays used to measure creatinine and albumin varied between studies that contributed data and a sex-specific definition was used for albuminuria rather than KDIGO guideline recommendations. CONCLUSIONS: This study provides evidence of a beneficial effect of coffee on kidney function. Given widespread coffee consumption and limited interventions to prevent CKD incidence and progression, this could have significant implications for global public health in view of the increasing burden of CKD worldwide.
RATIONALE & OBJECTIVE:Chronic kidney disease (CKD) is a leading cause of morbidity and mortality worldwide, with limited strategies for prevention and treatment. Coffee is a complex mixture of chemicals, and consumption has been associated with mostly beneficial health outcomes. This work aimed to determine the impact of coffee consumption on kidney function. STUDY DESIGN: Genome-wide association study (GWAS) and Mendelian randomization. SETTING & PARTICIPANTS: UK Biobank baseline data were used for a coffee consumption GWAS and included 227,666 participants. CKDGen Consortium data were used for kidney outcomes and included 133,814 participants (12,385 cases of CKD) of mostly European ancestry across various countries. EXPOSURE: Coffee consumption. OUTCOMES: Estimated glomerular filtration rate (eGFR), CKD GFR categories 3 to 5 (G3-G5; eGFR<60mL/min/1.73m2), and albuminuria. ANALYTICAL APPROACH: GWAS to identify single-nucleotide polymorphisms (SNPs) associated with coffee consumption in UK Biobank and use of those SNPs in Mendelian randomization analyses of coffee consumption and kidney outcomes in CKDGen. RESULTS: 2,126 SNPs were associated with coffee consumption (P<5×10-8), 25 of which were independent and available in CKDGen. Drinking an extra cup of coffee per day conferred a protective effect against CKD G3-G5 (OR, 0.84; 95% CI, 0.72-0.98; P=0.03) and albuminuria (OR, 0.81; 95% CI, 0.67-0.97; P=0.02). An extra cup was also associated with higher eGFR (β=0.022; P=1.6×10-6) after removal of 3 SNPs responsible for significant heterogeneity (Cochran Q P = 3.5×10-15). LIMITATIONS: Assays used to measure creatinine and albumin varied between studies that contributed data and a sex-specific definition was used for albuminuria rather than KDIGO guideline recommendations. CONCLUSIONS: This study provides evidence of a beneficial effect of coffee on kidney function. Given widespread coffee consumption and limited interventions to prevent CKD incidence and progression, this could have significant implications for global public health in view of the increasing burden of CKD worldwide.
Authors: Irma Karabegović; Eliana Portilla-Fernandez; Yang Li; Jiantao Ma; Silvana C E Maas; Daokun Sun; Emily A Hu; Brigitte Kühnel; Yan Zhang; Srikant Ambatipudi; Giovanni Fiorito; Jian Huang; Juan E Castillo-Fernandez; Kerri L Wiggins; Niek de Klein; Sara Grioni; Brenton R Swenson; Silvia Polidoro; Jorien L Treur; Cyrille Cuenin; Pei-Chien Tsai; Ricardo Costeira; Veronique Chajes; Kim Braun; Niek Verweij; Anja Kretschmer; Lude Franke; Joyce B J van Meurs; André G Uitterlinden; Robert J de Knegt; M Arfan Ikram; Abbas Dehghan; Annette Peters; Ben Schöttker; Sina A Gharib; Nona Sotoodehnia; Jordana T Bell; Paul Elliott; Paolo Vineis; Caroline Relton; Zdenko Herceg; Hermann Brenner; Melanie Waldenberger; Casey M Rebholz; Trudy Voortman; Qiuwei Pan; Myriam Fornage; Daniel Levy; Manfred Kayser; Mohsen Ghanbari Journal: Nat Commun Date: 2021-05-14 Impact factor: 14.919